These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 12771303

  • 1. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
    Tanaka R, Kakuta T, Fujisaki T, Tanaka S, Sakai H, Kurokawa K, Saito A.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
    [Abstract] [Full Text] [Related]

  • 2. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A.
    Am J Kidney Dis; 1999 Jun; 33(6):1091-9. PubMed ID: 10352197
    [Abstract] [Full Text] [Related]

  • 3. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients.
    Kakuta T, Kunimatsu K, Tadaki F, Fujisaki T, Noguchi M, Abe Y, Sakai H, Kurokawa K, Saito A.
    Biomed Pharmacother; 2000 Jun; 54 Suppl 1():60s-65s. PubMed ID: 10914993
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
    Tanaka M, Itoh K, Matsushita K, Matsushita K, Fukagawa M.
    Nephron Clin Pract; 2006 Feb; 102(1):c1-7. PubMed ID: 16166800
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
    Koiwa F, Kakuta T, Tanaka R, Yumita S.
    Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
    [Abstract] [Full Text] [Related]

  • 7. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients.
    Kitaoka M, Fukagawa M, Ogata E, Kurokawa K.
    Kidney Int; 1994 Oct; 46(4):1110-7. PubMed ID: 7861705
    [Abstract] [Full Text] [Related]

  • 8. Long-term prognosis of parathyroid function for chronic dialysis patients after minimally invasive radioguided parathyroidectomy (MIRP).
    Kakuta T, Suzuki Y, Tadaki F, Tanaka R, Tanaka S, Sakai H, Kurokawa K, Saito A.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii71-5. PubMed ID: 12771306
    [Abstract] [Full Text] [Related]

  • 9. [PEIT is the part of strategy for severe hyperparathyroidism in patients requiring hemodialysis].
    Uemura K, Kakuta T.
    Clin Calcium; 2004 Sep; 14(9):88-92. PubMed ID: 15577118
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism.
    Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E.
    Am J Kidney Dis; 1996 Nov; 28(5):704-12. PubMed ID: 9158208
    [Abstract] [Full Text] [Related]

  • 11. [A case of secondary hyperparathyroidism with an ectopic intrathyroid gland successfully diagnosed and controlled by percutaneous ethanol injection therapy (PEIT)].
    Tanaka M, Itoh K, Matsushita K, Ogawa A, Hirayama H, Tsunoda N, Yoshizumi K, Naruse M, Nonoguchi H, Tomita K.
    Nihon Jinzo Gakkai Shi; 2002 May; 44(4):409-13. PubMed ID: 12073627
    [Abstract] [Full Text] [Related]

  • 12. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
    Koiwa F, Hasegawa T, Kojima I, Ideura T.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
    [Abstract] [Full Text] [Related]

  • 13. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.
    Nakamura M, Fuchinoue S, Teraoka S.
    Am J Kidney Dis; 2003 Oct; 42(4):739-45. PubMed ID: 14520624
    [Abstract] [Full Text] [Related]

  • 14. Renoprotection following treatment of secondary hyperparathyroidism with percutaneous ethanol injection in pre-dialysis patients.
    Chen HH, Chen YC, Yeh JC.
    Nephron; 2002 Sep; 92(1):105-10. PubMed ID: 12187092
    [Abstract] [Full Text] [Related]

  • 15. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism.
    de Barros Gueiros JE, Chammas MC, Gerhard R, da Silva Dias Boilesen CF, de Oliveira IR, Moysés RM, Jorgetti V.
    Nephrol Dial Transplant; 2004 Mar; 19(3):657-63. PubMed ID: 14767023
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism.
    Nakanishi S, Yano S, Nomura R, Tsukamoto T, Shimizu Y, Shin J, Fukagawa M.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii47-9. PubMed ID: 12771300
    [Abstract] [Full Text] [Related]

  • 17. Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients.
    Yamamoto H, Katoh N, Takeyama H, Ikeda M, Yokoyama K, Shigematsu T, Kawaguchi Y, Hosoya T.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii50-2. PubMed ID: 12771301
    [Abstract] [Full Text] [Related]

  • 18. Intervention for recurrent secondary hyperparathyroidism from a residual parathyroid gland.
    Yumita S.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii62-4. PubMed ID: 12771304
    [Abstract] [Full Text] [Related]

  • 19. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.
    Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K.
    Nephron; 1994 Jun; 68(2):221-8. PubMed ID: 7830860
    [Abstract] [Full Text] [Related]

  • 20. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
    Kuzdak K, Rybińska A, Białas M.
    Endokrynol Pol; 2005 Jun; 56(6):891-6. PubMed ID: 16821207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.